Search results
Results from the WOW.Com Content Network
Patients with proliferative lupus nephritis—maintenance: hydroxychloroquine, low dose (2 –3mg/kg/d) versus maintenance hydroxychloroquine, high dose (4 –5.5 g/kg/d) www.kidney-international.org contents
The optimal treatment of lupus nephritis (LN) varies with the classification of the morphological findings present on kidney biopsy. Immunosuppressive therapy is used to treat active focal (class III) or diffuse (class IV) LN or lupus membranous nephropathy (class V LN), or a combination of either focal or diffuse (class III/IV) and membranous ...
Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient ...
Treatment. There's no cure for lupus nephritis. Treatment aims to: Reduce symptoms or make symptoms go away, called remission. Keep the disease from getting worse. Keep symptoms from coming back. Keep kidneys working well enough to not need a machine to filter waste from blood, called dialysis, or a kidney transplant. Supportive treatments
Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease.
Management of lupus nephritis has evolved considerably over the past years. Here, we provide a comprehensive review of clinical trials that form the basis for the Kidney Disease: Improving Global Outcomes and EULAR/ERA-EDTA updated guidelines and present day trials that will change the landscape of lupus nephritis therapy in years to come.
This abridged version of the 2023 GLOSEN Consensus Document on Lupus Nephritis provides practical and up-to-date recommendations on the diagnosis, monitoring and treatment of patients with lupus nephritis (LN), including special situations such as frequently relapsing patients, refractory LN, pregnancy and thrombotic microangiopathy.